The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | FLAURA2 outcomes by EGFR mutation subtype in advanced NSCLC
Samreen Ahmed, FRCP, MD, MBBS, MSc, University Hospitals of Leicester NHS Trust, Leicester, UK, discusses the Phase III FLAURA2 study (NCT04035486) of first-line osimertinib with or without platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). Subgroup analyses by EGFR mutation subtype (L858R and exon 19 deletion) showed consistent progression-free survival benefit with the combination over osimertinib monotherapy, with a trend toward improved overall survival. Safety findings were in line with the global analysis, confirming higher toxicity with combination therapy. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
FLAURA2 has been the biggest news in this conference. This was the final four-year overall survival data. So FLAURA2 is looking at EGFR mutant non-small cell lung cancer and randomizes patients to either osimertinib or osimertinib and chemotherapy. And now at four years at their final cut it looks like there’s a 10-month overall survival difference and improvement with the chemotherapy and osimertinib arm compared to osimertinib alone...
FLAURA2 has been the biggest news in this conference. This was the final four-year overall survival data. So FLAURA2 is looking at EGFR mutant non-small cell lung cancer and randomizes patients to either osimertinib or osimertinib and chemotherapy. And now at four years at their final cut it looks like there’s a 10-month overall survival difference and improvement with the chemotherapy and osimertinib arm compared to osimertinib alone. So that’s been probably the most practice-changing study presented in this conference. So I have a poster tomorrow looking at exploratory analysis of FLAURA2 by genomic subtypes. So the two common subtypes which were recruited to FLAURA2 were L858R and exon 19 deletion. Generally we think that the L858R population have a poorer outcome than perhaps the exon 19 deletion, but it looks like giving them FLAURA2 too, again gives them a 10 month benefit. So the group that you think are doing the worst also get a very good magnitude of overall survival difference.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
